Valuation: Tsubota Laboratory Incorporated

Market Cap 7.09B 44.47M 38.43M 36.05M 32.85M 61.69M 4.25B 62.63M 420M 165M 2.13B 167M 163M P/E 2025
49.7x
P/E 2026 -9.95x
Enterprise Value 6.19B 38.82M 33.54M 31.47M 28.68M 53.86M 3.71B 54.67M 366M 144M 1.86B 146M 143M EV / Sales 2025
6.38x
EV / Sales 2026 33.4x
Free-Float
28.38%
Yield 2025 *
-
Yield 2026 -
06-16 Tsubota Laboratory Incorporated announced that it has received ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
05-31 Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe CI
05-31 Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million. CI
05-15 Tsubota Laboratory Incorporated Reports Earnings Results for the Full Year Ended March 31, 2026 CI
05-15 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027 CI
02-13 Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
02-13 Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025 CI
25-05-11 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026 CI
25-02-17 Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
24-11-20 Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025 CI
22-12-18 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022. CI
22-09-19 Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022. CI
22-06-23 Tsubota Laboratory Incorporated has completed an IPO in the amount of Ñ1.8048 billion. CI
1 day-0.72%
1 week+5.77%
Current month+11.34%
1 month+16.03%
3 months+0.73%
6 months+3.38%
Current year-19.12%
1 week 267
Extreme 267
283
1 month 226
Extreme 226
288
Current year 210
Extreme 210
478
1 year 210
Extreme 210
478
3 years 210
Extreme 210
625
5 years 210
Extreme 210
1,447
10 years 210
Extreme 210
1,447
Manager TitleAgeSince
President 71 2019-01-31
Chief Administrative Officer - -
Chief Tech/Sci/R&D Officer 65 2024-12-31
Director TitleAgeSince
Director/Board Member 71 2019-01-31
Director/Board Member 70 2020-05-31
Director/Board Member 55 2023-05-31
Date Insider Type Main position Quantity % Market Cap.
11/15/24 Others

Founder

63,000 0.2465%
11/15/24 Others

Founder

420,000 1.6434%
Change 5-day change 1-year change 3-year change Capi.($)
-0.72%+5.77%-22.97%-43.42% 44.9M
+0.68%-1.01%+2.16%+18.05% 48.42B
+4.07%+3.34%+483.70%+609.03% 43.66B
+4.33%+4.09%+12.80%+88.48% 39.51B
+1.94%+1.06%+26.24%+12.10% 38.95B
-0.50%+0.85%+20.60%+58.18% 32.61B
-0.44%-3.14% - - 16.32B
+3.22%+1.09%+30.42%+133.64% 16.15B
-0.62%+0.29%+3.46%+25.58% 14.16B
+2.35%+7.16%+82.95%+41.92% 13.37B
Average +1.43%+0.34%+71.04%+104.84% 26.32B
Weighted average by Cap. +1.93%-0.62%+101.56%+147.48%

Financials

2025 2026
Net sales 1.36B 8.51M 7.35M 6.9M 6.28M 11.8M 814M 11.98M 80.29M 31.63M 407M 31.95M 31.26M 200M 1.25M 1.08M 1.02M 926K 1.74M 120M 1.77M 11.83M 4.66M 60.01M 4.71M 4.61M
Net income 205M 1.29M 1.11M 1.04M 949K 1.78M 123M 1.81M 12.13M 4.78M 61.51M 4.83M 4.72M -761M -4.77M -4.12M -3.87M -3.52M -6.62M -456M -6.72M -45.03M -17.74M -228M -17.92M -17.53M
Net Debt -1.45B -9.08M -7.84M -7.36M -6.71M -12.59M -868M -12.78M -85.68M -33.75M -434M -34.1M -33.36M -901M -5.65M -4.88M -4.58M -4.17M -7.84M -540M -7.95M -53.31M -21M -270M -21.22M -20.76M
Logo Tsubota Laboratory Incorporated
Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.
Employees
-
Date Price Change Volume
26-08-17 JP¥275.00 -0.72% 50,800
26-08-14 JP¥277.00 +0.36% 26,300
26-08-13 JP¥276.00 +0.36% 63,000
26-08-12 JP¥275.00 +2.23% 48,500
  1. Stock Market
  2. Stocks
  3. 4890 Stock